Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
159 studies found for:    "Gout"
Show Display Options
Rank Status Study
21 Completed
Has Results
A Proof-of-Concept Study of AC-201 to Prevent Gout Flares
Condition: Gout Flares
Interventions: Drug: Placebo;   Drug: AC-201;   Drug: Febuxostat
22 Recruiting Novel Methods for Ascertainment of Gout Flares -A Pilot Study
Condition: Gout
Interventions: Device: IVR (Phone call);   Device: RheumPro (Smartphone application)
23 Completed
Has Results
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study.
Condition: Acute Gout
Interventions: Drug: Canakinumab 150 mg;   Drug: Triamcinolone acetonide 40 mg;   Drug: Placebo to canakinumab;   Drug: Placebo to triamcinolone acetonide
24 Completed
Has Results
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study
Condition: Acute Gout
Interventions: Drug: Canakinumab 150 mg;   Drug: Triamcinolone acetonide 40 mg;   Drug: Placebo to canakinumab;   Drug: Placebo to triamcinolone acetonide
25 Completed
Has Results
Long-Term Safety of Febuxostat in Subjects With Gout.
Condition: Gout
Intervention: Drug: Febuxostat
26 Completed
Has Results
Dose-Response, Safety and Efficacy of Febuxostat in Subjects With Gout
Condition: Gout
Interventions: Drug: Placebo;   Drug: Febuxostat
27 Completed Colchicine Or Naproxen Treatment for ACute gouT
Condition: Gout
Interventions: Drug: Low-dose colchicine;   Drug: Naproxen 750 mg/250 mg
28 Completed RDEA3170 Monotherapy in Subjects With Gout
Condition: Gout
Interventions: Drug: Placebo;   Drug: RDEA3170 5 mg;   Drug: RDEA3170 10 mg;   Drug: RDEA3170 12.5 mg
29 Active, not recruiting DECT Study in Allopurinol-Treated Gout Patients
Condition: Gout
Intervention: Procedure: DECT scan
30 Completed
Has Results
Open-Label Lesinurad Monotherapy Extension Study in Gout
Condition: Gout
Intervention: Drug: lesinurad
31 Active, not recruiting Arthritis Research UK Gout Treatment Trial - Phase 2
Condition: Gout
Interventions: Other: Nurse intervention;   Other: Standard care
32 Completed
Has Results
Febuxostat Versus Allopurinol Control Trial in Subjects With Gout
Condition: Gout
Interventions: Drug: Febuxostat;   Drug: Allopurinol
33 Completed
Has Results
MPC-004 for the Treatment of an Acute Gout Flare
Condition: Gout
Interventions: Drug: High Dose Colchicine (4.8 mg total dose);   Drug: Low Dose Colchicine (1.8mg total dose);   Other: Placebo Control
34 Completed
Has Results
Efficacy and Safety of Oral Febuxostat in Participants With Gout
Condition: Gout
Interventions: Drug: Febuxostat;   Drug: Allopurinol
35 Completed Phase III Trial of Febuxostat in Korea Gout Patients
Condition: Gout
Intervention: Drug: Febuxostat
36 Completed RDEA3170 and Allopurinol Combination Study in Gout Subjects
Condition: Gout
Interventions: Drug: RDEA3170 10 mg;   Drug: allopurinol 300 mg
37 Completed A Study to Evaluate Safety and Efficacy of Oral Febuxostat in Patients With Gout
Condition: Gout
Interventions: Drug: febuxostat;   Drug: Allopurinol
38 Completed RDEA3170 and Febuxostat Combination Study in Gout Subjects
Condition: Gout
Interventions: Drug: RDEA3170 15 mg;   Drug: RDEA3170 10 mg;   Drug: RDEA3170 2.5;   Drug: RDEA3170 5 mg;   Drug: Febuxostat 40 mg;   Drug: Febuxostat 80 mg
39 Completed Phase 2a RDEA3170 and Allopurinol Combination Study in Gout Subjects
Condition: Gout
Interventions: Drug: RDEA3170 2.5 mg;   Drug: allopurinol 300 mg
40 Completed Study of the Safety and Effectiveness of Rilonacept for the Prevention of Gout Flares
Condition: Gout
Interventions: Biological: rilonacept;   Other: placebo

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.